Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced top-line results from the Phase 3 COMPASS PWS trial evaluating the ...

SGLT2 inhibitors may improve glycaemic control and renal markers without affecting body weight in patients with Prader-Willi syndrome and T2D, but they are tied to an elevated risk for adverse events.

Acadia Pharma (NASDAQ:ACAD) shares fell in the premarket on Wednesday after the biotech announced that its experimental ...

Acadia's Phase 3 Compass Prader-Willi syndrome trial failed to meet endpoints, but the company projects $1 billion in sales in 2025 and highlights a strong pipeline outlook.

Acadia Pharmaceuticals was testing the drug, an intranasal formulation of the oxytocin analogue carbetocin, for its potential ...

Actor Colin Farrell recently disclosed that his son, James, has Angelman syndrome, one of the driving factors behind Farrell's support for finding a cure for Angelman syndrome and for launching the ...

WE’LL TALK TO YOU LATER. WELL, IMAGINE EATING ENOUGH MAYBE TOO MUCH, BUT NEVER FEELING FULL. THAT’S WHAT A NORTHLAND TODDLER LIVES WITH EVERY DAY. AND THIS WORLD WHERE DISEASE DAY CAME DECISIONS DONNA ...

Prader-Willi syndrome is a genetic disorder that affects growth, behavior, and learning. There is no cure for the syndrome, but continual monitoring and treatment may improve a person’s quality of ...

How Does It Work for Excessive Hunger? Prader-Willi syndrome is a rare condition usually caused by genetic changes in your DNA. It can also occur after a head or brain injury. The condition affects ...